GoodRx (GDRX) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 10, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Central Index Key	0001809519
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Shell Company	false
Entity File Number	001-39549
Entity Tax Identification Number	47-5104396
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2701 Olympic
Entity Address, Address Line Two	Boulevard
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90404
City Area Code	855
Local Phone Number	268-2822
Trading Symbol	GDRX
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		69,555,726
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		323,389,392

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 990,463	$ 968,691
Restricted cash	2,900	2,900
Accounts receivable, net	74,399	68,729
Prepaid expenses and other current assets	55,618	46,048
Total current assets	1,123,380	1,086,368
Property and equipment, net	22,693	23,057
Goodwill	261,116	261,116
Intangible assets, net	34,443	36,919
Capitalized software, net	25,944	19,800
Operating lease right-of-use assets	27,883	27,712
Deferred tax assets, net	13,344	13,117
Other assets	2,171	2,025
Total assets	1,510,974	1,470,114
Current liabilities
Accounts payable	15,101	10,291
Accrued expenses and other current liabilities	34,944	37,692
Current portion of debt	7,029	7,029
Operating lease liabilities, current	5,975	4,539
Total current liabilities	63,049	59,551
Debt, net	658,883	659,888
Operating lease liabilities, net of current portion	33,705	33,467
Other liabilities	6,278	5,849
Total liabilities	761,915	758,755
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and zero shares issued and outstanding at March 31, 2021 and December 31, 2020
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 69,043 and 63,071 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively; and Class B: 1,000,000 shares authorized, 323,414 and 328,589 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	39	39
Additional paid-in capital	2,137,805	2,101,773
Accumulated deficit	(1,388,785)	(1,390,453)
Total stockholders' equity	749,059	711,359
Total liabilities and stockholders' equity	$ 1,510,974	$ 1,470,114

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	69,043,000	63,071,000
Common stock, shares outstanding	69,043,000	63,071,000
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	323,414,000	328,589,000
Common stock, shares outstanding	323,414,000	328,589,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 160,431	$ 133,408
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	10,428	6,019
Product development and technology	26,160	10,325
Sales and marketing	79,694	63,162
General and administrative	43,786	5,887
Depreciation and amortization	5,361	4,345
Total costs and operating expenses	165,429	89,738
Operating (loss) income	(4,998)	43,670
Other expense, net:
Other income, net		(5)
Interest income	(16)	(75)
Interest expense	5,905	8,638
Total other expense, net	5,889	8,558
(Loss) income before income taxes	(10,887)	35,112
Income tax benefit (expense)	12,555	(7,766)
Net income	1,668	27,346
Net income attributable to common stockholders
Basic	1,668	17,662
Diluted	$ 1,668	$ 17,832
Earnings per share:
Earnings per share - basic	$ 0	$ 0.08
Earnings per share - diluted	$ 0	$ 0.08
Weighted average shares used in computing earnings per share:
Basic	406,170	229,880
Diluted	429,577	236,225
Cost of Sales
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 121	$ 17
Research and Development Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	8,336	896
Selling and Marketing Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	5,258	870
General and Administrative Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 32,811	$ 427

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Redeemable Convertible Preferred Stock	Class A and Class B Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ (1,087,582)			$ 460	$ 8,788	$ (1,096,830)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019		126,046
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2019		$ 737,009
Beginning balance at Dec. 31, 2019				229,750
Stock options exercised	692			$ 1	691
Stock options exercised, Shares				467
Stock-based compensation	2,501				2,501
Net income	27,346					27,346
Ending balance at Mar. 31, 2020	(1,057,043)			$ 461	11,980	(1,069,484)
Redeemable convertible preferred stock, Ending balance, Shares at Mar. 31, 2020		126,046
Redeemable convertible preferred stock, Ending balance at Mar. 31, 2020		$ 737,009
Ending balance at Mar. 31, 2020				230,217
Beginning balance at Dec. 31, 2020	711,359		$ 39		2,101,773	(1,390,453)
Beginning balance at Dec. 31, 2020			391,660
Stock options exercised	2,680				2,680
Stock options exercised, Shares			513
Stock-based compensation	48,254				48,254
Vesting of restricted stock awards, Shares			608
Common stock withheld for tax obligations and net settlement	(14,902)				(14,902)
Common stock withheld for tax obligations and net settlement, Shares			(324)
Net income	1,668					1,668
Ending balance at Mar. 31, 2021	$ 749,059		$ 39		$ 2,137,805	$ (1,388,785)
Ending balance at Mar. 31, 2021			392,457

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net income	$ 1,668	$ 27,346
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,361	4,345
Amortization of debt issuance costs	863	783
Non-cash operating lease expense	872	1,152
Stock-based compensation	46,526	2,210
Deferred income taxes	(227)	2,292
Changes in operating assets and liabilities
Accounts receivable	(5,670)	(12,064)
Prepaid expenses and other assets	(9,844)	(2,821)
Accounts payable	4,943	7,254
Accrued expenses and other current liabilities	(67)	15,501
Operating lease liabilities	631	(427)
Other liabilities	429	21
Net cash provided by operating activities	45,485	45,592
Cash flows from investing activities
Purchase of property and equipment	(2,715)	(674)
Capitalized software	(6,980)	(2,733)
Net cash used in investing activities	(9,695)	(3,407)
Cash flows from financing activities
Proceeds from long-term debt		28,000
Payments on long-term debt	(1,757)	(1,757)
Proceeds from exercise of stock options	2,372	692
Proceeds from early exercise of stock options		667
Employee taxes paid related to net share settlement of equity awards	(14,633)
Net cash (used in) provided by financing activities	(14,018)	27,602
Net change in cash, cash equivalents and restricted cash	21,772	69,787
Cash, cash equivalents and restricted cash
Beginning of period	971,591	26,050
End of period	993,363	95,837
Non cash investing and financing activities
Stock-based compensation included in capitalized software development costs	1,728	291
Capitalized software development costs in accrued expenses and other current liabilities	615	119
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	990,463	95,837
Restricted cash	2,900
End of period	$ 993,363	$ 95,837

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2021
Description Of Business [Abstract]
Description of Business	1. Description of Business GoodRx Holdings, Inc. was incorporated in September 2015. On October 7, 2015, GoodRx Holdings, Inc. acquired 100% of the outstanding shares of GoodRx, Inc. (“GoodRx”). GoodRx, a Delaware corporation, was initially formed in September 2011. GoodRx Holdings, Inc. and its subsidiaries (the “Company”) offer information and tools to help consumers compare prices and save on their prescription drug purchases. The Company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States (the “prescription offering”). The services are free to consumers and the Company primarily earns revenue from its core business from pharmacy benefit managers (“PBMs”) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. The Company also offers other healthcare products and services, including subscriptions, pharmaceutical manufacturer solutions and telehealth services.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020 and the related notes, which are included in the Company's Annual Report on Form 10-K filed with the SEC on March 12, 2021. The December 31, 2020 condensed consolidated balance sheet was derived from the Company’s audited consolidated financial statements as of that date. The Company’s condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The Company’s significant accounting policies are discussed in “Note 2. Summary of Significant Accounting Policies” in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in accounting policies during the three months ended March 31, 2021 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2020 and the related notes. During the three months ended March 31, 2021 and 2020, other than net income, the Company did not have any other elements of comprehensive income or loss. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021. Principles of Consolidation The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs GoodRx Care, LLC (formerly known as HeyDoctor), a wholly owned subsidiary of the Company, provides management and other services to professional service corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws that restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Revenue of the VIEs were less than 3% and 1% of the Company’s revenue for the three months ended March 31, 2021 and 2020, respectively. The net results of operations of the VIEs for the three months ended March 31, 2021 and 2020 were not material. The VIEs’ total assets and liabilities were each approximately 1% of the Company’s total assets and liabilities at March 31, 2021 and December 31, 2020, respectively. Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three months ended March 31, 2021 and 2020, all of the Company’s revenue was from customers located in the United States. In addition, at March 31, 2021 and December 31, 2020, all of the Company’s right-of-use assets and property and equipment was in the United States. Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets and assumptions used for purposes of determining stock-based compensation. Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended March 31, 2021, four customers accounted for approximately 14%, 11%, 10% and 10% of the Company’s revenue. For the three months ended March 31, 2020, three customers accounted for approximately 18%, 18% and 12% of the Company’s revenue. At March 31, 2021, one customer accounted for 10% In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. The Company’s prescription offering sequentially increased beginning in the third quarter of 2020 through the first quarter of 2021 as consumers partially resumed their interaction with the healthcare system. In addition, the Company has experienced a significant increase in demand for its telehealth offerings. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, the actions to contain the virus or treat its impact, mutations of the virus, availability and adoption of effective vaccines and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill and other long-lived assets, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s condensed consolidated financial statements or annual consolidated financial statements in future periods. Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted primarily of U.S. treasury securities, money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of Restricted cash as of March 31, 2021 and December 31, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle, LLC business combination relating to contingent considerati Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combination	3. Business Combination Scriptcycle, LLC On August 31, 2020, the Company acquired all of the equity interests of Scriptcycle, LLC (“Scriptcycle”). Scriptcycle specializes in managing prescription programs and primarily partners with regional retail pharmacy chains to provide discount offerings. The purpose of the acquisition was to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The aggregate purchase consideration was $58.3 million, including the estimated fair value of contingent consideration of $0.8 million. The purchase consideration was subject to working capital and other closing adjustments. The maximum amount of contingent consideration payable was $2.9 million subject to the achievement of certain revenue thresholds through January 2021. As of March 31, 2021 and December 31, 2020, the fair value of the contingent consideration was $2.9 million, which represents the maximum amount of contingent consideration payable, based upon the Company’s assessment of the revenue thresholds that were achieved. Goodwill associated with this acquisition totaled $24.9 million and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill was deductible for tax purposes. Unaudited supplemental pro forma financial information for the Scriptcycle acquisition have not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Income taxes receivable $ 41,392 $ 28,564 Prepaid expenses 14,226 17,484 Total prepaid expenses and other current assets $ 55,618 $ 46,048

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Accrued bonus and other payroll related $ 11,375 $ 13,607 Accrued marketing 9,554 10,045 Deferred revenue 8,804 6,852 Other accrued expenses 5,211 7,188 Total accrued expenses and other current liabilities $ 34,944 $ 37,692 The Company expects substantially all of the deferred revenue at March 31, 2021 will be recognized as revenue within the next twelve months. Of the $6.9 million deferred revenue included in the condensed consolidated balance sheet at December 31, 2020, $4.3 million was recognized as revenue during the three months ended March 31, 2021. Revenue recognized during the three months ended March 31, 2020 of $1.9 million was included as deferred revenue at December 31, 2019.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The Company calculates income taxes in interim periods by applying an estimated annual effective tax rate to (loss) income before income taxes and by calculating the tax effect of discrete items recognized during the period. The effective income tax rate was 115.3% and 22.1% for the three months ended March 31, 2021 and 2020, respectively. The change in the Company’s effective income tax rate for the three months ended March 31, 2021 compared to the three months ended March 31, 2020 was primarily due to the change from pre-tax income to loss in addition to the tax effects of nondeductible officers’ stock-based compensation expense and excess tax benefits related to the Company’s equity awards. The Company’s effective income tax rate differs from the U.S. Federal statutory rate of 21.0% primarily due to effects of non-deductible officers’ stock-based compensation expense, state income taxes, benefits from research and development tax credits, and excess tax benefits from the Company’s equity awards. As of December 31, 2020, the Company had unrecognized tax benefits of $7.4 million. There were no significant changes to the Company’s unrecognized tax benefits during the three months ended March 31, 2021, and the Company does not expect to have any significant changes to unrecognized tax benefits through the end of 2021.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	7. Debt The Company has a term loan with an original amount of $700.0 million (the “First Lien Term Loan Facility”) The Company also has a line of credit with a maximum amount of $100.0 million (the “Revolving Credit Facility”) The Company’s debt consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Principal balance under First Lien Term Loan Facility $ 679,369 $ 681,126 Less: Unamortized debt issuance costs and discounts (13,457 ) (14,209 ) $ 665,912 $ 666,917 As of March 31, 2021, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Credit Agreement. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At March 31, 2021, the Company was in compliance with its covenants.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Aside from the below, as of March 31, 2021, there were no material changes to the Company’s commitments and contingencies as disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Purchase Commitments The Company entered into a commercial agreement with a third-party during the quarter ended March 31, 2021, pursuant to which the Company committed to spend an aggregate of at least $3.0 million by the end of the fiscal year ending December 31, 2021 on certain advertising services. Legal Contingencies On December 18, 2020, R. Brian Terenzini, individually and on behalf of all others similarly situated, filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:20-cv-11444). On January 8, 2021, Bryan Kearney, individually and on behalf of all others similarly situated, also filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:21-cv-00175). The plaintiffs seek compensatory damages as well as interest, fees and costs. The complaints allege violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and assert that the Company failed to disclose to investors that Amazon.com, Inc. was developing its own mobile and online prescription medication ordering and fulfillment service that would compete directly with the Company. According to the complaint, when Amazon announced its competitor service, the Company’s stock price fell, causing investor losses. Lead plaintiff applications were submitted February 16, 2021, and on April 8, 2021, the court consolidated the two lawsuits and appointed lead plaintiffs. The Company intends to seek dismissal of the consolidated case. The Company believes it has meritorious defenses to the claims of the plaintiffs and members of the class and any liability for the alleged claims is not currently probable and a loss or range of loss, if any, is not reasonably estimable. On April 29, 2021 and May 5, 2021, Neesha Patel and Wayne Geist, respectively, each filed a derivative lawsuit purportedly on behalf of the Company against certain of its officers and directors in the United States District Court for the Central District of California (Case No. 2:21-cv-03671 and Case No. 2:21-cv-03829, respectively). The plaintiffs assert claims for breach of fiduciary duty and contribution under the Exchange Act. Neesha Patel asserts additional claims for unjust enrichment and corporate waste. These claims are based on allegations substantially similar to those in the class action lawsuit described above. Plaintiffs are requesting declaratory relief, money damages, restitution, and certain governance reforms. Plaintiffs did not make a pre-suit demand on the Company’s board. The Company intends to seek dismissal of these cases, or a stay pending the outcome of the class action lawsuit. Any liability for the claims alleged is not currently probable and a loss or range of loss, if any, is not reasonably estimable. The pending proceedings described above involve complex questions of fact and law and may require the expenditure of significant funds and the diversion of other resources to defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. In addition, during the normal course of business, the Company may become subject to, and is presently involved in, legal proceedings, claims and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated. The Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its consolidated financial statements. Indemnification The Company’s amended and restated bylaws provides that it will indemnify the Company’s directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. Pursuant to the Company’s indemnification agreements and directors’ and officers’ liability insurance, certain of the Company’s officers and directors will be indemnified and insured against the cost of defense, settlement or payment of a judgment under certain circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is indeterminable. The Company has never paid a material claim, nor has the Company been involved in litigation, with respect to these indemnification arrangements. As of March 31, 2021 and December 31, 2020, the Company has not accrued a liability for these guarantees as, the likelihood of incurring a payment obligation, if any, in connection with these guarantees is not probable or reasonably estimable.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue	9. Revenue Revenue consisted of the following: Three Months Ended March 31, (in thousands) 2021 2020 Prescription transactions revenue $ 134,061 $ 123,017 Other revenue 26,370 10,391 Total revenue $ 160,431 $ 133,408

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation Stock Options A summary of the stock option activity for the three months ended March 31, 2021 is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic (in thousands, except per share amounts and term information) Shares Price Term Value Outstanding at December 31, 2020 21,528 $ 6.22 Granted — — Exercised (513 ) 5.23 Expired / Cancelled / Forfeited (253 ) 6.07 Outstanding at March 31, 2021 20,762 $ 6.24 7.9 years $ 680,528 Exercisable at March 31, 2021 9,812 $ 3.92 7.0 years $ 344,350 There were no stock options granted during the three months ended March 31, 2021. The weighted-average grant date fair value per share of stock options granted for the three months ended March 31, 2020 was $2.95. The aggregate intrinsic value of options exercised for the three months ended March 31, 2021 and 2020 was $18.7 million and $1.4 million, respectively. All options outstanding at March 31, 2021 are options to purchase shares of Class A common stock. The fair value of option awards issued with service or service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The Company does not have material stock options issued with market vesting conditions. For the three months ended March 31, 2021 and 2020, the stock-based compensation expense related to stock options was $4.2 million and $1.7 million, respectively. At March 31, 2021, there was $32.0 million of total unrecognized stock-based compensation cost related to stock options, which is expected to be recognized over a weighted average remaining service period of 2.8 years. Restricted Stock Awards and Restricted Stock Units A summary of the Restricted Stock Awards (“RSAs”) and Restricted Stock Unit (“RSUs”) activity is as follows: Restricted Restricted Stock Units for Class A Restricted Stock Units for Class B Weighted Average Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted stock awards or restricted stock units at December 31, 2020 1,409 2,790 7,698 $ 26.74 Granted — 647 — 44.12 Vested — (95 ) (513 ) 29.12 Forfeited — (17 ) — 42.31 Nonvested restricted stock awards or restricted stock units at March 31, 2021 1,409 3,325 7,185 $ 28.05 There were no RSUs granted or outstanding during the three months ended March 31, 2020. There were no RSAs that vested during three months ended March 31, 2021 and 2020. Restricted Stock Awards For the three months ended March 31, 2021 and 2020, total stock-based compensation expense related to RSAs was $0.5 million, respectively. At March 31, 2021, there was $3.7 million of total unrecognized stock-based compensation cost related to these RSAs which is expected to be recognized over the remaining service period of 2.0 years. There were no RSAs granted subsequent to December 31, 2019. Restricted Stock Units for Class A Common Stock For the three months ended March 31, 2021 At March 31, 2021 Restricted Stock Units for Class B Common Stock On September 11, 2020, the board of directors granted RSUs covering an aggregate of 24,633,066 shares of Class B common stock to the Company’s Co-Chief Executive Officers (the “Founders Awards”), subject to the completion of the Company’s initial public offering (“IPO”). Each of the Co-Chief Executive Officers received (i) 8,211,022 RSUs that vest based on the achievement of stock price goals ranging from $6.07 per share to $51.28 per share, subject to continued employment through the applicable vesting date (the “Performance-Vesting Founders Awards”) and (ii) 4,105,511 RSUs that vest and settle in equal quarterly installments over four years, subject to continued employment through the applicable vesting date (the “Time-Vesting Founders Awards”). The grant date fair value of these awards was $533.3 million. The Performance-Vesting Founders Awards vested during the fourth quarter of 2020 and will be settled in shares of common stock in October 2023 or, if earlier, upon a qualifying change in control event or to satisfy tax withholding requirements. The Time-Vesting Founders Awards are subject to vesting acceleration terms upon a qualifying change in control. All the stock price goals with respect to the Performance-Vesting Founders Awards were achieved as of October 22, 2020. As a result, all 16,422,044 Performance-Vesting Founders Awards vested during the year ended December 31, 2020. As of December 31, 2020, the Company has recognized a cumulative $373.0 million of stock-based compensation expense related to the Founders Awards, of which $53.2 million related to the Time-Vesting Founders Awards and $319.8 million related to the Performance-Vesting Founders Awards. As the Performance-Vesting Founders Awards vested in October 2020, the Company settled 0.7 million RSUs during the fourth quarter of 2020, sufficient to satisfy FICA tax withholding obligations due in the year of vesting. The remaining 15.7 million Performance-Vesting Founders Awards shares will not be issued until October 2023 or, if earlier, a change in control event, as defined in the RSU agreements governing the Founders Awards. During the three months ended March 31, 2021, the Company has recognized $30.0 million of stock-based compensation expense related to the Time-Vesting Founders Awards. At March 31, 2021, there was $130.3 million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, which is expected to be recognized over the weighted average remaining service period of 2.0 years.

Basic and Diluted Earnings Per

Basic and Diluted Earnings Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	11. Basic and Diluted Earnings Per Share The computation of earnings per share for the three months ended March 31, 2021 and 2020 is as follows: Three Months Ended March 31, (in thousands, except per share amounts) 2021 2020 Numerator: Net income $ 1,668 $ 27,346 Less: Undistributed earnings allocated to convertible preferred stock — (9,684 ) Net income attributable to common stockholders - basic $ 1,668 $ 17,662 Add: Undistributed earnings reallocated to holders of common stock — 170 Net income attributable to common stockholders - diluted $ 1,668 $ 17,832 Denominator: Weighted average shares - basic 406,170 229,880 Dilutive impact of stock options, restricted stock awards and restricted stock units 23,407 6,345 Weighted average shares - diluted 429,577 236,225 Earnings per share Basic $ 0.00 $ 0.08 Diluted $ 0.00 $ 0.08 The following weighted average potentially dilutive shares were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive: Three Months Ended March 31, (in thousands) 2021 2020 Redeemable convertible preferred stock — 126,046 Stock options, restricted stock awards and restricted stock units 531 11,063

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On April 16 HealthiNation Inc. (“HealthiNation”) $ 75.0 On April 30 The above two acquisitions will be accounted for as business combinations under Accounting Standard Codification 805, Business Combinations HealthiNation and RxSaver On April 20, 2021, the Company’s board of directors granted RSUs for 0.2 million shares of Class A common stock to employees, which will substantially vest over a four-year On April 29, 2021 and May 5, 2021, Neesha Patel and Wayne Geist, respectively, each filed a derivative lawsuit purportedly on behalf of the Company against certain of its officers and directors in the United States District Court for the Central District of California (Case No. 2:21-cv-03671 and Case No. 2:21-cv-03829, respectively), see “Note 8 – Commitments and Contingencies – Legal Contingencies.”

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020 and the related notes, which are included in the Company's Annual Report on Form 10-K filed with the SEC on March 12, 2021. The December 31, 2020 condensed consolidated balance sheet was derived from the Company’s audited consolidated financial statements as of that date. The Company’s condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The Company’s significant accounting policies are discussed in “Note 2. Summary of Significant Accounting Policies” in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in accounting policies during the three months ended March 31, 2021 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2020 and the related notes. During the three months ended March 31, 2021 and 2020, other than net income, the Company did not have any other elements of comprehensive income or loss. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs GoodRx Care, LLC (formerly known as HeyDoctor), a wholly owned subsidiary of the Company, provides management and other services to professional service corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws that restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Revenue of the VIEs were less than 3% and 1% of the Company’s revenue for the three months ended March 31, 2021 and 2020, respectively. The net results of operations of the VIEs for the three months ended March 31, 2021 and 2020 were not material. The VIEs’ total assets and liabilities were each approximately 1% of the Company’s total assets and liabilities at March 31, 2021 and December 31, 2020, respectively.
Segment Reporting and Geographic Information	Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three months ended March 31, 2021 and 2020, all of the Company’s revenue was from customers located in the United States. In addition, at March 31, 2021 and December 31, 2020, all of the Company’s right-of-use assets and property and equipment was in the United States.
Use of Estimates	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets and assumptions used for purposes of determining stock-based compensation.
Certain Risks and Concentrations	Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended March 31, 2021, four customers accounted for approximately 14%, 11%, 10% and 10% of the Company’s revenue. For the three months ended March 31, 2020, three customers accounted for approximately 18%, 18% and 12% of the Company’s revenue. At March 31, 2021, one customer accounted for 10% In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. The Company’s prescription offering sequentially increased beginning in the third quarter of 2020 through the first quarter of 2021 as consumers partially resumed their interaction with the healthcare system. In addition, the Company has experienced a significant increase in demand for its telehealth offerings. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, the actions to contain the virus or treat its impact, mutations of the virus, availability and adoption of effective vaccines and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill and other long-lived assets, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s condensed consolidated financial statements or annual consolidated financial statements in future periods.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted primarily of U.S. treasury securities, money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of Restricted cash as of March 31, 2021 and December 31, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle, LLC business combination relating to contingent considerati
Recent Accounting Pronouncements	Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Income taxes receivable $ 41,392 $ 28,564 Prepaid expenses 14,226 17,484 Total prepaid expenses and other current assets $ 55,618 $ 46,048

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Accrued bonus and other payroll related $ 11,375 $ 13,607 Accrued marketing 9,554 10,045 Deferred revenue 8,804 6,852 Other accrued expenses 5,211 7,188 Total accrued expenses and other current liabilities $ 34,944 $ 37,692

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s debt consisted of the following: (in thousands) March 31, 2021 December 31, 2020 Principal balance under First Lien Term Loan Facility $ 679,369 $ 681,126 Less: Unamortized debt issuance costs and discounts (13,457 ) (14,209 ) $ 665,912 $ 666,917

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Summary of Revenue	Revenue consisted of the following: Three Months Ended March 31, (in thousands) 2021 2020 Prescription transactions revenue $ 134,061 $ 123,017 Other revenue 26,370 10,391 Total revenue $ 160,431 $ 133,408

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Summary of Stock Option Activity	A summary of the stock option activity for the three months ended March 31, 2021 is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic (in thousands, except per share amounts and term information) Shares Price Term Value Outstanding at December 31, 2020 21,528 $ 6.22 Granted — — Exercised (513 ) 5.23 Expired / Cancelled / Forfeited (253 ) 6.07 Outstanding at March 31, 2021 20,762 $ 6.24 7.9 years $ 680,528 Exercisable at March 31, 2021 9,812 $ 3.92 7.0 years $ 344,350
Restricted Stock
Summary of Restricted Stock Activity	A summary of the Restricted Stock Awards (“RSAs”) and Restricted Stock Unit (“RSUs”) activity is as follows: Restricted Restricted Stock Units for Class A Restricted Stock Units for Class B Weighted Average Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted stock awards or restricted stock units at December 31, 2020 1,409 2,790 7,698 $ 26.74 Granted — 647 — 44.12 Vested — (95 ) (513 ) 29.12 Forfeited — (17 ) — 42.31 Nonvested restricted stock awards or restricted stock units at March 31, 2021 1,409 3,325 7,185 $ 28.05

Basic and Diluted Earnings Pe_2

Basic and Diluted Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule Computation of Earnings Per Share	The computation of earnings per share for the three months ended March 31, 2021 and 2020 is as follows: Three Months Ended March 31, (in thousands, except per share amounts) 2021 2020 Numerator: Net income $ 1,668 $ 27,346 Less: Undistributed earnings allocated to convertible preferred stock — (9,684 ) Net income attributable to common stockholders - basic $ 1,668 $ 17,662 Add: Undistributed earnings reallocated to holders of common stock — 170 Net income attributable to common stockholders - diluted $ 1,668 $ 17,832 Denominator: Weighted average shares - basic 406,170 229,880 Dilutive impact of stock options, restricted stock awards and restricted stock units 23,407 6,345 Weighted average shares - diluted 429,577 236,225 Earnings per share Basic $ 0.00 $ 0.08 Diluted $ 0.00 $ 0.08
Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Earnings Per Share	The following weighted average potentially dilutive shares were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive: Three Months Ended March 31, (in thousands) 2021 2020 Redeemable convertible preferred stock — 126,046 Stock options, restricted stock awards and restricted stock units 531 11,063

Description of Business - Addit

Description of Business - Additional Information (Details)	3 Months Ended
	Mar. 31, 2021	Oct. 07, 2015
Description Of Business [Line Items]
Entity incorporation month and year	2015-09
GoodRx, Inc.
Description Of Business [Line Items]
Percentage of outstanding shares acquired		100.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2021USD ($)segmentCustomer	Mar. 31, 2020Customer	Dec. 31, 2020USD ($)Customer
Accounting Policies [Line Items]
Variable interest entity's percentage of total assets and liabilities	1.00%		1.00%
Number of operating segment | segment	1
Accounting Standards Update 2018-15
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle accounting standards update adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting Standards Update 2018-17
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle accounting standards update adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting Standards Update 2019-12
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, early adoption [true false]	true
Change in accounting principle accounting standards update adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Money Market Funds | Fair Value, Inputs, Level 1
Accounting Policies [Line Items]
Cash equivalents, fair value disclosure | $	$ 932.5		$ 932.5
Customer Concentration Risk | Revenue From Customer
Accounting Policies [Line Items]
Number of customers	4	3
Customer Concentration Risk | Revenue From Customer | Customer One
Accounting Policies [Line Items]
Concentration risk percentage	14.00%	18.00%
Customer Concentration Risk | Revenue From Customer | Customer Two
Accounting Policies [Line Items]
Concentration risk percentage	11.00%	18.00%
Customer Concentration Risk | Revenue From Customer | Customer Three
Accounting Policies [Line Items]
Concentration risk percentage	10.00%	12.00%
Customer Concentration Risk | Revenue From Customer | Customer Four
Accounting Policies [Line Items]
Concentration risk percentage	10.00%
Credit Concentration Risk | Accounts Receivable
Accounting Policies [Line Items]
Number of customers	1		1
Credit Concentration Risk | Accounts Receivable | Customer One
Accounting Policies [Line Items]
Concentration risk percentage	10.00%		12.00%
Maximum
Accounting Policies [Line Items]
Variable interest entity's percentage of total revenue	3.00%	1.00%

Business Combination - Addition

Business Combination - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 261,116	$ 261,116
Scriptcycle LLC
Business Acquisition [Line Items]
Date of acquisition	Aug. 31, 2020
Business combination, aggregate consideration	$ 58,300
Estimated fair value of contingent consideration	800
Contingent consideration based on achievement of certain revenue thresholds	2,900	$ 2,900	$ 2,900
Goodwill	24,900
Identifiable intangible assets related to acquisition	28,300
Acquired current assets	5,900
Assumed liabilities	1,100
Scriptcycle LLC | Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition	$ 25,300
Identifiable intangible assets estimated useful life	11 years
Scriptcycle LLC | Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition	$ 3,000
Scriptcycle LLC | Developed Technology and Tradename | Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life	1 year
Scriptcycle LLC | Developed Technology and Tradename | Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life	9 years

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Income taxes receivable	$ 41,392	$ 28,564
Prepaid expenses	14,226	17,484
Total prepaid expenses and other current assets	$ 55,618	$ 46,048

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued bonus and other payroll related	$ 11,375	$ 13,607
Accrued marketing	9,554	10,045
Deferred revenue	8,804	6,852
Other accrued expenses	5,211	7,188
Total accrued expenses and other current liabilities	$ 34,944	$ 37,692

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Payables And Accruals [Abstract]
Deferred revenue	$ 8,804		$ 6,852
Revenue recognized	$ 4,300	$ 1,900

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax rate	115.30%	22.10%
Federal statutory rate	21.00%	21.00%
Unrecognized tax benefits			$ 7,400,000
Changes in unrecognized tax benefits	$ 0

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
First Lien Credit Agreement
Debt Instrument [Line Items]
Maximum net leverage ratio	8.20%
Covenant terms	As of March 31, 2021, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Credit Agreement. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company.  At March 31, 2021, the Company was in compliance with its covenants.
First Lien Term Loan Facility | First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit	$ 700,000,000
Percentage of collateralized assets	100.00%
Frequency of interest payment	quarterly
Line of credit maturity date	Oct. 10, 2025
Description of payments	The First Lien Term Loan Facility requires quarterly payments through September 2025, with any unpaid principal and interest due upon maturity on October 10, 2025
Effective interest rate	3.39%	5.05%
First Lien Term Loan Facility | Minimum | First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts	2.75%
First Lien Term Loan Facility | Maximum | First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts	3.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit	$ 100,000,000
Line of credit maturity date	Oct. 11, 2024
Principal balance	$ 0		$ 0
Revolving Credit Facility | Minimum | First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts	2.50%
Interest rate on unused amounts	0.25%
Revolving Credit Facility | Maximum | First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts	3.00%
Interest rate on unused amounts	0.50%
Letter of Credit
Debt Instrument [Line Items]
Principal balance	$ 9,100,000		$ 9,100,000

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - First Lien Term Loan Facility - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal balance	$ 679,369	$ 681,126
Less: Unamortized debt issuance costs and discounts	(13,457)	(14,209)
Total debt	$ 665,912	$ 666,917

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	Mar. 31, 2021USD ($)
Purchase Commitment
Purchase Commitment Excluding Longterm Commitment [Line Items]
Aggregate purchase commitment minimum amount committed	$ 3

Revenue - Summary of Revenue (D

Revenue - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 160,431	$ 133,408
Prescription Transactions Revenue
Disaggregation Of Revenue [Line Items]
Revenue	134,061	123,017
Other Revenue
Disaggregation Of Revenue [Line Items]
Revenue	$ 26,370	$ 10,391

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, shares	0
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding, Beginning balance	21,528,000
Exercised, shares	(513,000)
Expired / Cancelled / Forfeited, shares	(253,000)
Shares outstanding, Ending Balance	20,762,000
Exercisable at March 31, 2021	9,812,000
Weighted Average Exercise Prices, Beginning balance | $ / shares	$ 6.22
Weighted Average Exercise Prices, Exercised | $ / shares	5.23
Weighted Average Exercise Prices, Expired/ Cancelled/ Forfeited | $ / shares	6.07
Weighted Average Exercise Prices, Ending balance | $ / shares	6.24
Weighted Average Exercise Prices, Exercisable at March 31, 2021 | $ / shares	$ 3.92
Weighted average remaining contractual term, Outstanding	7 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding | $	$ 680,528
Aggregate Intrinsic Value, Exercisable | $	$ 344,350

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 11, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		0
Weighted-average grant date fair value of stock options granted				$ 2.95
Aggregate intrinsic value of options exercised		$ 18.7		$ 1.4
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		4.2		$ 1.7
Unrecognized stock-based compensation cost		$ 32
Weighted-average period over which cost is expected to be recognized		2 years 9 months 18 days
Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted				0
Restricted shares outstanding				0
Restricted Stock Units ("RSUs") | Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 11.8
Weighted-average period over which cost is expected to be recognized		3 years 7 months 6 days
Unrecognized stock-based compensation cost		$ 124.1
Restricted Stock Units ("RSUs") | Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense					$ 373
Grant date fair value	$ 533.3
Restricted Stock Units ("RSUs") | Common Class B | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted	24,633,066
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 0.5		$ 0.5
Weighted-average period over which cost is expected to be recognized		2 years
Restricted shares granted		0				0
Restricted shares outstanding		1,409,000	1,409,000		1,409,000
Shares vested		0		0
Unrecognized stock-based compensation cost		$ 3.7
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense					$ 319.8
Shares vested					16,422,044
Shares for tax withholding obligations			700,000
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Common Class B | Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares not issued until three years from vesting date							15,700,000
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Common Class B | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested	8,211,022
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Common Class B | Co-Chief Executive Officers | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 6.07
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Common Class B | Co-Chief Executive Officers | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 51.28
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards | Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 30			$ 53.2
Weighted-average period over which cost is expected to be recognized		2 years
Unrecognized stock-based compensation cost		$ 130.3
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards | Common Class B | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested and settled	4,105,511
Vesting period	4 years

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	1,409,000
Granted	0		0
Vested	0	0
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	1,409,000
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	2,790,000
Granted	647,000
Vested	(95,000)
Forfeited	(17,000)
Nonvested restricted stock awards or restricted stock units, Ending Balance	3,325,000
Restricted Stock Units for Class B Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	7,698,000
Granted	0
Vested	(513,000)
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	7,185,000
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Beginning Balance	$ 26.74
Granted, Weighted Average Grant Date Fair Value	44.12
Vested, Weighted Average Grant Date Fair Value	29.12
Forfeited, Weighted Average Grant Date Fair Value	42.31
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Ending Balance	$ 28.05

Basic and Diluted Earnings Pe_3

Basic and Diluted Earnings Per Share - Schedule Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net income	$ 1,668	$ 27,346
Less: Undistributed earnings allocated to convertible preferred stock		(9,684)
Net income attributable to common stockholders - basic	1,668	17,662
Add: Undistributed earnings reallocated to holders of common stock		170
Net income attributable to common stockholders - diluted	$ 1,668	$ 17,832
Denominator:
Weighted average shares - basic	406,170	229,880
Dilutive impact of stock options, restricted stock awards and restricted stock units	23,407	6,345
Weighted average shares - diluted	429,577	236,225
Earnings per share:
Basic	$ 0	$ 0.08
Diluted	$ 0	$ 0.08

Basic and Diluted Earnings Pe_4

Basic and Diluted Earnings Per Share - Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted earnings per share		126,046
Stock Options, Restricted Stock Awards and Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted earnings per share	531	11,063

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Apr. 30, 2021	Apr. 20, 2021	Apr. 16, 2021	Mar. 31, 2021	Mar. 31, 2020
Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Number of shares granted					0
Class A Common Stock | Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Weighted-average period over which cost is expected to be recognized				3 years 7 months 6 days
Subsequent Event | Board of Directors | Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Vesting period		4 years
Estimated grant date fair value		$ 7.9
Weighted-average period over which cost is expected to be recognized		4 years
Subsequent Event | Class A Common Stock | Board of Directors | Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Number of shares granted		200,000
Subsequent Event | HealthiNation Inc.
Subsequent Event [Line Items]
Business combination, consideration paid in cash			$ 75
Subsequent Event | RxSaver, Inc.
Subsequent Event [Line Items]
Business combination, consideration paid in cash	$ 50